Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Mirum Pharmaceuticals (MIRM) Return on Sales (2021 - 2025)

Mirum Pharmaceuticals has reported Return on Sales over the past 5 years, most recently at 0.04% for Q4 2025.

  • Quarterly results put Return on Sales at 0.04% for Q4 2025, up 20.0% from a year ago — trailing twelve months through Dec 2025 was 0.04% (up 22.0% YoY), and the annual figure for FY2025 was 0.04%, up 22.0%.
  • Return on Sales for Q4 2025 was 0.04% at Mirum Pharmaceuticals, down from 0.02% in the prior quarter.
  • Over the last five years, Return on Sales for MIRM hit a ceiling of 18.25% in Q4 2021 and a floor of 9.42% in Q3 2021.
  • Median Return on Sales over the past 5 years was 0.49% (2023), compared with a mean of 0.42%.
  • Peak annual rise in Return on Sales hit 752bps in 2022, while the deepest fall reached -1956bps in 2022.
  • Mirum Pharmaceuticals' Return on Sales stood at 18.25% in 2021, then tumbled by -107bps to 1.31% in 2022, then soared by 61bps to 0.51% in 2023, then skyrocketed by 53bps to 0.24% in 2024, then surged by 84bps to 0.04% in 2025.
  • The last three reported values for Return on Sales were 0.04% (Q4 2025), 0.02% (Q3 2025), and 0.05% (Q2 2025) per Business Quant data.